Clinical Utility of Prenatal Whole Exome Sequencing

NACompletedINTERVENTIONAL
Enrollment

316

Participants

Timeline

Start Date

August 1, 2017

Primary Completion Date

May 13, 2022

Study Completion Date

May 13, 2022

Conditions
Structural AnomaliesCardiac AnomaliesCentral Nervous System AnomaliesThorax AnomaliesGenito-urinary AnomaliesGastrointestinal AnomaliesSkeletal AnomaliesMultiple Anomalies
Interventions
DEVICE

Whole Exome Sequencing (WES)

The Investigators will enroll pregnant women with fetal anomalies detected by ultrasound. Patients will be approached by a maternal-fetal specialist, who has counseled the patient regarding the fetal anomaly that has been detected. Written informed consent will be obtained by the study prenatal genetic counselor. Many patients will have undergone prenatal diagnostic testing in an outside laboratory; in such cases, cells or extracted DNA from the original fetal sample will be used for the purpose of this study. The consent process for prenatal WES will include pre-test counseling and the option of choosing whether or not to receive uncertain results and secondary findings. After conducting whole exome sequencing, the findings will be shared with the parent(s). Routine medical care will be provided to patients. The research will study the effectiveness of sequencing as a tool for providing genetic information to parents when a prenatal study reveals a fetus with a structural anomaly.

Trial Locations (1)

94143

University of California San Francisco, San Francisco

All Listed Sponsors
lead

University of California, San Francisco

OTHER

NCT03482141 - Clinical Utility of Prenatal Whole Exome Sequencing | Biotech Hunter | Biotech Hunter